Regional Combined with Systemic Chemotherapy in Unresectable Biliary Tract Cancers: A Phase II Study

M. Cantore, G. Fiorentini, A. Mambrini, C. Rabbi, D. Zamagni, N. Carlone, Andrea Manni, R. Caudana, T. Torri

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Unresectable biliary tract cancers have a very poor prognosis. No good systemic chemotherapeutic regimen is available. This study aimed to evaluated the activity and toxicity of a novel approach of combined loco-regional and systemic chemotherapy. Twenty four patients with advanced or metastatic biliary tumors were treated with epiadriamycin 50 mg/m 2 and cisplatin 60 mg/m 2 administered bolus in proper hepatic artery on day 1, combined with systemic continuous infusion of 5-fluorouracil 200 mg/m 2/day, from day 1 to day 14, every 3 weeks. The overall response rate was 8/24 (33%), including one complete response and 7 partial responses (stable disease 46%, progression 21%). The treatment was well tolerated with a minimal hematological toxicity; the major clinical problem was the deep venous thrombosis related to central venous catheter, that occurred in 5 patients (21%). Median overall survival was 14,6 months and 1-year and 2-year survival were 54% and 38% respectively. Performance status improved in 33% of patients and weight gain more than 7% was observed in 17%. This novel combined loco-regional and systemic chemotherapeutic regimen is active and safe for advanced biliary tract cancer patients.

Original languageEnglish (US)
Pages (from-to)59-64
Number of pages6
JournalJournal of Experimental and Clinical Cancer Research
Volume22
Issue number4 SUPPL.
StatePublished - Dec 1 2003

Fingerprint

Biliary Tract Neoplasms
Drug Therapy
Survival
Central Venous Catheters
Hepatic Artery
Venous Thrombosis
Fluorouracil
Cisplatin
Weight Gain
Disease Progression
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cantore, M., Fiorentini, G., Mambrini, A., Rabbi, C., Zamagni, D., Carlone, N., ... Torri, T. (2003). Regional Combined with Systemic Chemotherapy in Unresectable Biliary Tract Cancers: A Phase II Study. Journal of Experimental and Clinical Cancer Research, 22(4 SUPPL.), 59-64.
Cantore, M. ; Fiorentini, G. ; Mambrini, A. ; Rabbi, C. ; Zamagni, D. ; Carlone, N. ; Manni, Andrea ; Caudana, R. ; Torri, T. / Regional Combined with Systemic Chemotherapy in Unresectable Biliary Tract Cancers : A Phase II Study. In: Journal of Experimental and Clinical Cancer Research. 2003 ; Vol. 22, No. 4 SUPPL. pp. 59-64.
@article{f7fd0814113742428f90eb98ce36d242,
title = "Regional Combined with Systemic Chemotherapy in Unresectable Biliary Tract Cancers: A Phase II Study",
abstract = "Unresectable biliary tract cancers have a very poor prognosis. No good systemic chemotherapeutic regimen is available. This study aimed to evaluated the activity and toxicity of a novel approach of combined loco-regional and systemic chemotherapy. Twenty four patients with advanced or metastatic biliary tumors were treated with epiadriamycin 50 mg/m 2 and cisplatin 60 mg/m 2 administered bolus in proper hepatic artery on day 1, combined with systemic continuous infusion of 5-fluorouracil 200 mg/m 2/day, from day 1 to day 14, every 3 weeks. The overall response rate was 8/24 (33{\%}), including one complete response and 7 partial responses (stable disease 46{\%}, progression 21{\%}). The treatment was well tolerated with a minimal hematological toxicity; the major clinical problem was the deep venous thrombosis related to central venous catheter, that occurred in 5 patients (21{\%}). Median overall survival was 14,6 months and 1-year and 2-year survival were 54{\%} and 38{\%} respectively. Performance status improved in 33{\%} of patients and weight gain more than 7{\%} was observed in 17{\%}. This novel combined loco-regional and systemic chemotherapeutic regimen is active and safe for advanced biliary tract cancer patients.",
author = "M. Cantore and G. Fiorentini and A. Mambrini and C. Rabbi and D. Zamagni and N. Carlone and Andrea Manni and R. Caudana and T. Torri",
year = "2003",
month = "12",
day = "1",
language = "English (US)",
volume = "22",
pages = "59--64",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central",
number = "4 SUPPL.",

}

Cantore, M, Fiorentini, G, Mambrini, A, Rabbi, C, Zamagni, D, Carlone, N, Manni, A, Caudana, R & Torri, T 2003, 'Regional Combined with Systemic Chemotherapy in Unresectable Biliary Tract Cancers: A Phase II Study', Journal of Experimental and Clinical Cancer Research, vol. 22, no. 4 SUPPL., pp. 59-64.

Regional Combined with Systemic Chemotherapy in Unresectable Biliary Tract Cancers : A Phase II Study. / Cantore, M.; Fiorentini, G.; Mambrini, A.; Rabbi, C.; Zamagni, D.; Carlone, N.; Manni, Andrea; Caudana, R.; Torri, T.

In: Journal of Experimental and Clinical Cancer Research, Vol. 22, No. 4 SUPPL., 01.12.2003, p. 59-64.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regional Combined with Systemic Chemotherapy in Unresectable Biliary Tract Cancers

T2 - A Phase II Study

AU - Cantore, M.

AU - Fiorentini, G.

AU - Mambrini, A.

AU - Rabbi, C.

AU - Zamagni, D.

AU - Carlone, N.

AU - Manni, Andrea

AU - Caudana, R.

AU - Torri, T.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Unresectable biliary tract cancers have a very poor prognosis. No good systemic chemotherapeutic regimen is available. This study aimed to evaluated the activity and toxicity of a novel approach of combined loco-regional and systemic chemotherapy. Twenty four patients with advanced or metastatic biliary tumors were treated with epiadriamycin 50 mg/m 2 and cisplatin 60 mg/m 2 administered bolus in proper hepatic artery on day 1, combined with systemic continuous infusion of 5-fluorouracil 200 mg/m 2/day, from day 1 to day 14, every 3 weeks. The overall response rate was 8/24 (33%), including one complete response and 7 partial responses (stable disease 46%, progression 21%). The treatment was well tolerated with a minimal hematological toxicity; the major clinical problem was the deep venous thrombosis related to central venous catheter, that occurred in 5 patients (21%). Median overall survival was 14,6 months and 1-year and 2-year survival were 54% and 38% respectively. Performance status improved in 33% of patients and weight gain more than 7% was observed in 17%. This novel combined loco-regional and systemic chemotherapeutic regimen is active and safe for advanced biliary tract cancer patients.

AB - Unresectable biliary tract cancers have a very poor prognosis. No good systemic chemotherapeutic regimen is available. This study aimed to evaluated the activity and toxicity of a novel approach of combined loco-regional and systemic chemotherapy. Twenty four patients with advanced or metastatic biliary tumors were treated with epiadriamycin 50 mg/m 2 and cisplatin 60 mg/m 2 administered bolus in proper hepatic artery on day 1, combined with systemic continuous infusion of 5-fluorouracil 200 mg/m 2/day, from day 1 to day 14, every 3 weeks. The overall response rate was 8/24 (33%), including one complete response and 7 partial responses (stable disease 46%, progression 21%). The treatment was well tolerated with a minimal hematological toxicity; the major clinical problem was the deep venous thrombosis related to central venous catheter, that occurred in 5 patients (21%). Median overall survival was 14,6 months and 1-year and 2-year survival were 54% and 38% respectively. Performance status improved in 33% of patients and weight gain more than 7% was observed in 17%. This novel combined loco-regional and systemic chemotherapeutic regimen is active and safe for advanced biliary tract cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=1842583344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842583344&partnerID=8YFLogxK

M3 - Article

C2 - 16767908

AN - SCOPUS:1842583344

VL - 22

SP - 59

EP - 64

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 4 SUPPL.

ER -

Cantore M, Fiorentini G, Mambrini A, Rabbi C, Zamagni D, Carlone N et al. Regional Combined with Systemic Chemotherapy in Unresectable Biliary Tract Cancers: A Phase II Study. Journal of Experimental and Clinical Cancer Research. 2003 Dec 1;22(4 SUPPL.):59-64.